Treatments for Chronic Respiratory Illnesses

EpiEndo Pharmaceuticals is pioneering a novel approach to treating chronic inflammatory diseases, particularly those affecting the epithelium, such as chronic obstructive pulmonary disease (COPD). Their lead compound, EP395, is an oral, barrier-enhancing, and anti-inflammatory drug designed to improve epithelial function and reduce inflammation. This innovative therapeutic strategy is based on over 20 years of research into macrolides, which has revealed their potential to mitigate COPD exacerbations without significant antibacterial effects. EpiEndo's Barriolides™ represent a new class of drugs that enhance epithelial barrier function by strengthening cell junctions and improving the immune response of epithelial cells, thereby addressing the underlying causes of chronic inflammation rather than merely treating symptoms.

The company's research emphasizes the importance of the epithelial barrier in lung health, positing that its dysfunction is a key driver of chronic airway diseases. EpiEndo's Barriolides™ have shown superior efficacy in preclinical studies compared to traditional treatments like azithromycin, particularly in environments exposed to pollutants and pathogens. Importantly, these compounds are designed to minimize the risk of antimicrobial resistance, a significant concern with long-term use of conventional macrolides. EpiEndo's commitment to developing first-in-class therapies is supported by a robust intellectual property portfolio, ensuring the protection of their innovative therapeutic assets and the Barriolide™ concept until at least 2036.

Iceland

EpiEndo Pharmaceuticals is an Icelandic clinical stage pharmaceutical company with a unique focus on impairment of epithelial barriers as a common mechanism of many inflammatory conditions such as the airway, gastrointestinal tract and skin. EpiEndo was founded in 2014.

EpiEndo Pharmaceuticals

Company Details